News
Welcome to Logical Therapeutics’ newsroom.
-
May 27, 2010
Logical Therapeutics Secures $16.9M Series C Financing Round
Lead Candidate, LT-NS001, Shows Evidence of Improved GI Safety for Arthritis Patients -
April 26, 2010
Logical Therapeutics Initiates Enrollment In In New Gastrointestinal Safety Study in Osteoarthritis Patients -
October 27, 2009
Logical Therapeutics Announces Positive Results of LT-NS001 vs. Naproxen Clinical Study
-
October 20, 2009
Logical Therapeutics to Present Data on LT-NS001 at American College of Gastroenterology Annual Meeting
-
May 11, 2009
Logical Therapeutics Appoints Peter A. Lankau as CEO and Director
-
September 8, 2008
Logical Therapeutics Inc. Commences Double-Blind, Randomized Study of their lead program, LT-NS001.
-
August 19, 2008
Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
-
June 13, 2007
Logical Therapeutics Inc. Raises US $30M Series B to Advance Drug Pipeline Targeting Inflammatory Diseases - Naproxen Pro-drug to enter Phase 2 Clinical Development
-
September 5, 2006
Logical Therapeutics Inc. in-licenses novel anti-inflammatory drug
-
August 10, 2006
Logical Therapeutics Inc. Launches Operations with Seed Capital from PA Early Stage Partners
Contact Us
124 Washington Street, Suite 101
Foxboro, MA 02035
781.290.0900 phone
781.290.0911 fax
info@logicaltx.com